RxDoctor Payments Data

Mohammad Jondy

Family Medicine · Grand Blanc, MINPI 1912312489

Payments from drug & device makers

$5,263in general payments, 2019–2025

Across 292 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pacira Pharmaceuticals Incorporated$795
  • Novo Nordisk$710
  • Pfizer$436
  • Lilly USA, LLC$411
  • AbbVie$394
  • GSK$350
  • plus $2K from 40 others

What the payments were for

  • Travel & lodging$56211%
  • Food & beverage$4,70089%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,263 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$1,006,678
Medicare patients
520
Services billed
7,029

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide42$60,231
JardianceEmpagliflozin31$41,945
EliquisApixaban34$37,833
OzempicSemaglutide21$36,742
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$19,687
VraylarCariprazine Hcl11$16,111
JanumetSitagliptin Phos/Metformin Hcl11$13,340
XareltoRivaroxaban13$11,664
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$8,486
PaxlovidNirmatrelvir/Ritonavir13$5,647
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,718
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$2,195
Niacin ErNiacin11$1,539
Levothyroxine Sodium118$1,445
Atorvastatin Calcium147$1,341

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$411$60,23142 claims
PfizerEliquis, Paxlovid$436$43,48047 claims
Boehringer IngelheimJardiance$187$41,94531 claims
Novo NordiskOzempic$710$36,74221 claims
GSKTrelegy Ellipta$350$19,68722 claims
AbbVieVraylar$394$16,11111 claims
MerckJanumet$26$13,34011 claims
Johnson & JohnsonXarelto$86$11,66413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Grand Blanc

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →